Please select the option that best describes you:
How do you approach the outpatient management of bispecific antibody therapy for hematologic malignancies?
Can grade 1 toxicities (e.g. CRS) be monitored safely as an outpatient?
Can grade 1 toxicities (e.g. CRS) be monitored safely as an outpatient?